Minerva Neurosciences, Inc. (NERV) Key Metrics
NERV valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $112.2M
- Enterprise value
- $91.4M
- P/E (TTM)
- —
- Forward P/E
- 11.2
- PEG ratio
- —
- Price / sales
- 1.9
- Price / book
- 2.7
- EV / EBITDA
- 2.6
- Dividend yield
- —
- Beta
- −0.12
NERV key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNERV returns How much profit the business earns on the capital it uses.
NERV financial health Debt, liquidity and how easily interest is covered.
NERV efficiency & capital use Working capital cycle and where the cash goes.
NERV returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NERV debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NERV cash returned to shareholders
NERV key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $4.02 | $2.22 | $6.15 | $1.59 | $6.41 | $18.72 | $56.88 | $53.92 | $48.40 | $94.00 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | −164.6% | 4.8% | −122.3% | −45.2% | −26.5% | −38.5% |
| Return on invested capital (ROIC) | — | −134.9% | −120.7% | — | — | 38.4% | — | −0.2% | −166.4% | −73.7% |
| Return on assets (ROA) | −434.3% | 3.1% | −53.6% | −48.6% | −74.1% | 2.9% | −66.6% | −31.1% | −19.9% | −28.8% |
| Return on tangible assets | −353.1% | — | −71.4% | −79.9% | −80.2% | 7.0% | −152.2% | −55.7% | −23.4% | −37.0% |
| Free cash flow margin | — | — | — | — | — | −82.1% | −105.5% | — | — | — |
| Income quality (OCF / net income) | — | −13.59 | — | — | — | −17.43 | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $65.0M | $60.0M | $82.0M | $73.7M | — | $111,229 | $284,130 | $41.18B | $4.0M | $8.7M |
| Cash & short-term investments | $82.3M | $21.4M | $40.9M | $36.1M | $60.8M | $25.4M | $45.9M | $88.0M | $128.2M | $83.0M |
| Net debt | −$17.3M | $38.6M | $41.1M | $37.6M | −$60.8M | −$25.2M | −$45.6M | $41.09B | −$124.2M | −$74.3M |
| Debt / equity | — | — | — | — | — | 0.00 | 0.01 | 456.16 | 0.03 | 0.08 |
| Debt / assets | 0.66 | 1.62 | 1.44 | 1.34 | — | 0.00 | 0.00 | 295.94 | 0.02 | 0.07 |
| Net debt / EBITDA | — | 6.41 | — | — | — | −11.93 | — | — | — | — |
| Current ratio | 36.29 | 7.85 | 12.57 | 29.15 | 22.07 | 8.68 | 7.11 | 24.94 | 18.94 | 8.66 |
| Quick ratio | 36.29 | 7.85 | 12.57 | 31.34 | 22.07 | 8.68 | 7.11 | 24.94 | 18.94 | 8.66 |
| Interest coverage | — | -4.8 | -2.8 | -3.4 | -7.2 | — | -47.8 | -468.4 | -67.0 | -29.3 |
| Working capital | $80.8M | $19.4M | $38.7M | $38.8M | $59.4M | $24.3M | $40.5M | $86.4M | $122.7M | $74.2M |
| Invested capital | −$158.1M | $12.9M | $12.6M | $17.6M | −$52.8M | $27.4M | −$17.8M | $41.18B | $7.4M | $31.7M |
| Tangible asset value | −$155.6M | −$14.90B | −$43.3M | −$34.9M | −$6.9M | $22.6M | −$2.3M | $41.2M | $82.5M | $56.9M |
| Net current asset value | −$155.6M | −$40.6M | −$43.4M | −$35.0M | −$6.9M | $22.5M | −$2.6M | $41.1M | $77.4M | $56.9M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $10.5M | $0 |
| Share buybacks (net) | — | — | — | — | — | $0 | $0 | $0 | $389 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | — | 344.9% | — |
| Capex / revenue | — | — | — | — | — | 0.0% | 0.0% | — | — | — |
| Capex / operating cash flow | — | — | — | — | — | — | — | — | 1.7% | — |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 1.92 | 0.16 | 0.09 | 0.00 | 0.00 | 4.72 | 3.17 |
| Stock-based compensation / revenue | — | — | — | — | — | 23.6% | 22.3% | — | — | — |
| R&D / revenue | — | — | — | — | — | 53.5% | 141.2% | — | — | — |
| SG&A / revenue | — | — | — | — | — | 42.0% | 43.1% | — | — | — |
| Efficiency | ||||||||||
| Days of inventory on hand | — | — | — | -129,365.0 | — | — | — | — | — | — |
| Days payables outstanding | 75,349.0 | 27,722.7 | 16,346.1 | 60,516.4 | 5,107.9 | 3,431.5 | 4,651.8 | 33,803.3 | 47,771.4 | 31,232.7 |
| Receivables turnover | — | — | — | 0.00 | — | — | — | — | — | — |
| Payables turnover | 0.00 | 0.01 | 0.02 | 0.01 | 0.07 | 0.11 | 0.08 | 0.01 | 0.01 | 0.01 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.61 | 0.38 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | $3.1M | — | — | — | — | — | — |
| Average payables | $1.1M | $1.7M | $1.4M | $1.4M | $1.4M | $1.7M | $2.1M | $1.6M | $1.5M | $1.4M |
| Average inventory | — | — | — | −$3.0M | — | — | — | — | $0 | $0 |
| Intangibles / total assets | 15.2% | 40,032.0% | 26.2% | 27.1% | 19.3% | 52.2% | 38.8% | 35.3% | 26.7% | 36.9% |
Computed from NERV's annual financial statements (latest annual report filed March 11, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NERV valuation and financial ratios
It ended the year with $65.0 million of debt and $82.3 million in cash and short-term investments, a net cash position of $17.3 million.
See the NERV income statement, the NERV chart for price history, or the NERV stock overview for the latest quote and news.
NERV key metrics FAQ
How much debt does Minerva Neurosciences have?
Minerva Neurosciences had total debt of $65.0 million at the end of fiscal 2025 and more cash than debt.
What is Minerva Neurosciences's current ratio?
Minerva Neurosciences's current ratio was 36.29 at the end of fiscal 2025: current assets were 36.29 times current liabilities.